This company has been marked as potentially delisted and may not be actively trading. Ariad Pharmaceuticals (ARIA) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock ARIA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period After layoffs, new CEO Harvey Berger promises hiring at Arena BioWorksSeptember 9, 2025 | bizjournals.comHemab Therapeutics Expands Leadership with Appointment of Anant Murthy, PhD, as Chief Operating OfficerSeptember 2, 2025 | finance.yahoo.comARIAD Stock Price HistoryJune 1, 2025 | investing.comResolution Therapeutics Announces £63.5 Million Series B Financing and Chair AppointmentOctober 3, 2024 | finance.yahoo.comSolu Therapeutics Strengthens Leadership Team with Appointment of Sergio Santillana, MD, as Chief Medical OfficerSeptember 10, 2024 | finance.yahoo.comAffimed Appoints Shawn Leland As New CEOSeptember 3, 2024 | markets.businessinsider.comTerns Pharmaceuticals Finance Chief Vignola LeavingJuly 29, 2024 | marketwatch.comIDRx Appoints David P. Kerstein, M.D., as Chief Medical OfficerMarch 27, 2024 | finance.yahoo.comIDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBOMarch 12, 2024 | finance.yahoo.comWhat Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDAMarch 8, 2024 | msn.comTakeda extends lease in Kendall Square through 2040March 4, 2024 | bizjournals.comIncyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D PrioritiesFebruary 13, 2024 | finance.yahoo.comVeteran biotech entrepreneur Harvey Berger to lead startup Kojin TherapeuticsJanuary 3, 2024 | msn.comHarvey Berger leaves biotech 'sidelines' for new CEO gigJanuary 3, 2024 | bizjournals.comBiogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's TreatmentOctober 26, 2023 | msn.comLeukemia Therapeutics Treatment Market Set to Achieve US$ 30,318.5 Million by 2033 at 7.1% CAGR | Future Market Insights Inc.October 12, 2023 | benzinga.comKickstarter’s new finance chief is ultra-extroverted—and she credits that trait to her success as a ‘people-centric CFO’September 6, 2023 | fortune.comChronic Lymphocytic Leukemia Treatment Global Market Report 2023August 24, 2023 | finance.yahoo.comAriad Stock Falls On Unusually High Volume (ARIA)August 20, 2023 | thestreet.comSecond Alzheimer’s drug to slow disease’s progression may be approved in the US this yearJuly 18, 2023 | msn.comSecond Alzheimer's drug to slow disease's progression may be approved in the US this yearJuly 17, 2023 | cbsnews.comSarissa Capital Urges Alkermes Shareholders to Vote "FOR" Sarah Schlesinger and "WITHHOLD" Incumbent Director Richard GaynorJune 28, 2023 | finance.yahoo.comActivist Pro Tip: Don’t Put Your Girlfriend on the BoardJune 26, 2023 | washingtonpost.comPonatinib Market Research | 2023-2030May 16, 2023 | marketwatch.comComprehensive Analysis of Cancer Treatment Drugs Market Trends and Growth 2023-2030May 16, 2023 | marketwatch.comIclusig Market Research | 2023-2030May 14, 2023 | marketwatch.comUterine Cancer Therapies and Diagnostic Market Forecast 2023-2030May 10, 2023 | marketwatch.comThe Global Targeted Drugs for NSCLC Market Size is expanding rapidly, with a CAGR of 12.2% from 2023 to 2030May 5, 2023 | marketwatch.comChronic Myeloid Leukemia (CML) Treatment Market 2023 [New Report forecast 2030] Current and Future TrendsMay 5, 2023 | marketwatch.comEli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also RisesMay 3, 2023 | msn.comAcute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Analysis and Forecast to 2031May 3, 2023 | marketwatch.comCancer Drugs Market Applications and Types with Regional Analysis 2023-2031May 3, 2023 | marketwatch.comStomach Cancer Drugs Market (2023-2030) Rivalry Heats Up with New CAGR StatusApril 28, 2023 | marketwatch.comGlobal Gastric Cancer Drugs Market Report 2023: Increasing Number of Obesity Cases and the Smoking Population Drives GrowthApril 20, 2023 | benzinga.com2023-2030 Chronic Myeloid Leukemia (CML) Treatment Market Size with ManufacturesApril 20, 2023 | marketwatch.com2023-2030 Ponatinib Market Size Detailed Report with Downstream Market Analysis | Research by Absolute ReportsApril 19, 2023 | marketwatch.comUnlock Vital Data on Ponatinib market: Financial Summary, Shareholding Patterns, and Revenue Mix with Predicted CAGR of 5.1% from 2023-2030April 12, 2023 | marketwatch.comChronic Myeloid Leukemia (CML) Treatment Market 2023 Size and Forecast to 2031April 8, 2023 | marketwatch.comIn-depth Cancer Treatment Drugs report provides key estimates for predicting a projected CAGR of 5.2%April 8, 2023 | marketwatch.comPonatinib Market Research Analysis 2023-2030April 7, 2023 | marketwatch.comBile Duct Cancer Drug Market Growing Demand and Trends 2023 to 2031March 29, 2023 | marketwatch.comAnti-Cancer Drug Market Size and Forecast till 2031March 27, 2023 | marketwatch.comGlobal Cancer Drugs Market 2023 Projection, Growth Rate and Emerging Trends Analysis to 2030 By VMReportsMarch 26, 2023 | marketwatch.comIclusig Market Top Players and Forecast till 2031March 22, 2023 | marketwatch.comPonatinib Market Size 2023 to 2028 By Deployment, Growth Factor and Production costMarch 14, 2023 | marketwatch.comThe Evolution of Bile Duct Cancer Drug Market 2023: Future Developments and Trends by 2028March 11, 2023 | marketwatch.com2023-2029 Anti-Cancer Drug Market Size and Latest Trends Analysis | Research Report by Absolute ReportsMarch 10, 2023 | marketwatch.comGrowth Analysis on Proto-Oncogene Drgu Market Size 2023-2028 with Prominent Manufacturers | Research Report by Absolute ReportsMarch 8, 2023 | marketwatch.comForecasting the Future of Chronic Myeloid Leukemia (CML) Treatment Market: Analysing Emerging Trends and Opportunities 2023-2028March 7, 2023 | marketwatch.comGlobal Targeted Drug EGFR RTK Inhibitors for NSCLC Market Opportunities, Business Statistics Research Report 2030 By VMReportsMarch 4, 2023 | marketwatch.com Get Ariad Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARIA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARIA Media Mentions By Week ARIA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARIA News Sentiment▼0.000.73▲Average News Sentiment ARIA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARIA Articles This Week▼00▲ARIA Articles Average Week Get the Latest News and Ratings for ARIA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Ariad Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Amgen News Gilead Sciences News Vertex Pharmaceuticals News Alnylam Pharmaceuticals News Regeneron Pharmaceuticals News Biogen News United Therapeutics News Incyte News Neurocrine Biosciences News BioMarin Pharmaceutical News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARIA) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ariad Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ariad Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARIA Stock Alerts